#### 1 Leveraging chorionic villus biopsies for the derivation of patient-specific trophoblast 2 stem cells

- 3
- 4 Kaela M. Varberg<sup>1,†,‡</sup>, Ayelen Moreno-Irusta<sup>1,†</sup>, Allynson Novoa<sup>2</sup>, Brynne Musser<sup>1</sup>, Joseph M. 5 Varberg<sup>3</sup>, Jeremy P. Goering<sup>4</sup>, Irfan Saadi<sup>4</sup>, Khursheed Igbal<sup>1,§</sup>, Hiroaki Okae<sup>5</sup>, Takahiro Arima<sup>6</sup>, 6 John Williams III<sup>7,8</sup>, Margareta D. Pisarska<sup>2,7,8,9\*</sup>, and Michael J. Soares<sup>1,4,10,\*</sup>
- 7
- 8 <sup>1</sup>Institute for Reproductive and Developmental Sciences, Department of Pathology & Laboratory 9
- Medicine, University of Kansas Medical Center, Kansas City, KS 66160
- 10 <sup>2</sup>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and
- Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA 11
- 12 <sup>3</sup>Stowers Institute for Medical Research, Kansas City, MO, 64110
- 13 <sup>4</sup>Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, 14 KS 66160
- 15 <sup>5</sup>Department of Trophoblast Research. Institute of Molecular Embryology and Genetics.
- 16 Kumamoto University, Kumamoto 860-0811, Japan
- 17 <sup>6</sup>Department of Informative Genetics, Environment and Genome Research Center, Tohoku
- 18 University Graduate School of Medicine, Sendai 980-8575, Japan
- 19 <sup>7</sup>Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA
- <sup>8</sup>David Geffen School of Medicine, University of California, Los Angeles, CA 20
- 21 <sup>9</sup>Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA
- 22 <sup>10</sup>Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, 23 KS 66160 24
- 25 **Running title:** Chorionic villus-derived human TS cells
- 26 27 <sup>†</sup>These authors contributed equally.
- 28 29 <sup>‡</sup>Present address: Department of Pediatrics, Children's Mercy Research Institute, Children's 30 Mercy, Kansas City, MO 64108
- 31
- 32 <sup>§</sup>Present address: Department of Animal and Food Sciences, Oklahoma State University,
- 33 Stillwater, OK 74078
- 34

35 The authors have declared that no conflict of interest exists.

#### 36 37 \*Correspondence:

- 38 Margareta D. Pisarska, 8635 West Third Street, Suite 160W, Los Angeles, CA 90048,
- 39 (310)-423-5763, margareta.pisarska@cshs.org;
- 40 Michael J. Soares, Institute for Reproductive and Developmental Sciences, University of Kansas
- 41 Medical Center, Kansas Citv, KS, 66160.
- 42 (913)-588-5691, msoares@kumc.edu
- 43
- 44 Keywords: trophoblast stem cells, chorionic villus, placental development

### 45 Abstract

46 Human trophoblast stem (**TS**) cells are an informative in vitro model for the generation 47 and testing of biologically meaningful hypotheses. The goal of this project was to derive patient-48 specific TS cell lines from clinically available chorionic villus sampling biopsies. Cell outgrowths 49 were captured from human chorionic villus tissue specimens cultured in modified human TS cell 50 medium. Cell colonies emerged early during the culture and cell lines were established and 51 passaged for several generations. Karyotypes of the newly established chorionic villus-derived 52 trophoblast stem (**TS<sup>cv</sup>**) cell lines were determined and compared to initial genetic diagnoses from freshly isolated chorionic villi. Phenotypes of TS<sup>CV</sup> cells in the stem state and following 53 differentiation were compared to cytotrophoblast-derived TS (**TS**<sup>CT</sup>) cells. TS<sup>CV</sup> and TS<sup>CT</sup> cells 54 55 uniformly exhibited similarities in the stem state and following differentiation into 56 syncytiotrophoblast and extravillous trophoblast cells. Chorionic villus tissue specimens provide 57 a valuable source for TS cell derivation. They expand the genetic diversity of available TS cells and are associated with defined clinical outcomes. TS<sup>CV</sup> cell lines provide a new set of 58 59 experimental tools for investigating trophoblast cell lineage development. 60 61 Summary statement 62 The chorionic villus-derived trophoblast stem cell lines described in this report enhance

the genetic diversity of available trophoblast stem cell models and are linked to specific clinical
 outcomes. They offer a novel set of experimental tools for studying trophoblast cell lineage
 development and human placentation.

66

#### 67 Introduction

The placenta is a critical organ that allows the fetus to develop within the female reproductive tract (Amoroso, 1968). Specialized functions attributed to the placenta are executed by trophoblast cells (Knöfler et al., 2019, Soares et al., 2018, Turco and Moffett,

71 2019). The trophoblast cell lineage arises from the initial differentiation event of the embryo 72 (Rossant and Tam, 2017). In the human, trophoblast cells organize into villous and extravillous 73 structures. A villous is comprised of trophoblast and non-trophoblast cell types and includes a 74 self-renewing trophoblast cell population referred to as cytotrophoblast (Aplin and Jones, 2021, 75 Sun et al., 2020). Cytotrophoblast are the progenitors for two differentiated cell populations: 76 syncytiotrophoblast (STB) and extravillous trophoblast cells (EVT) (Knöfler et al., 2019, Soares 77 et al., 2018, Turco and Moffett, 2019). STB have a fundamental role in regulating nutrient and 78 waste transfer between mother and fetus (Aplin and Jones, 2021), whereas EVT cells exit the 79 placenta and transform the uterus into an environment supporting placental and fetal 80 development (Knöfler et al., 2019, Soares et al., 2018). Failures in placentation are the root 81 cause of an assortment of disorders of pregnancy, including pregnancy loss, preeclampsia, 82 intrauterine growth restriction, and pre-term birth (Brosens et al., 2019, Burton et al., 2016). 83 Regulatory mechanisms underlying human cytotrophoblast self-renewal and differentiation have 84 largely remained elusive.

85

86 Recently, conditions for capturing and maintaining human trophoblast stem (TS) cells in 87 vitro were described (Okae et al., 2018). Human TS cells have the capacity for self-renewal and 88 differentiation into STB cells or EVT. This in vitro model system has led to the generation of new 89 insights into mechanisms regulating human trophoblast cell development (Bhattacharya et al., 90 2020, Hornbachner et al., 2021, Ishiuchi et al., 2019, Jaju Bhattad et al., 2020, Muto et al., 91 2021, Perez-Garcia et al., 2021, Ruane et al., 2022, Saha et al., 2020, Shannon et al., 2022, 92 Sheridan et al., 2021, Takahashi et al., 2019, Varberg et al., 2021). Initial human TS cell lines 93 were derived from blastocysts, or first trimester placental tissue obtained from pregnancy 94 terminations. Establishment of culture conditions for human TS cells led to the derivation of TS 95 cells from pluripotent stem cells (Castel et al., 2020, Cinkornpumin et al., 2020, Dong et al., 96 2020, Guo et al., 2021, lo et al., 2021, Liu et al., 2020, Wei et al., 2021, Yanagida et al., 2021).

97 These in vitro model systems have provided new insights regarding trophoblast cell

98 development; however, it is unknown whether the origin of these TS cells was compatible with a

- 99 healthy pregnancy outcome.
- 100

101	Chorionic villus sampling (CVS) represents a standard, prenatal care procedure that is
102	performed between 10-14 weeks of gestation (Stranc et al., 1997). Sampling involves the
103	removal of a small amount of chorionic villus tissue, for the purpose of genetic testing. Common
104	indications for retrieving chorionic villus tissue include advanced maternal age, history of
105	infertility, family history (e.g., sibling with genetic anomalies), or an abnormal noninvasive
106	prenatal test result (Pisarska et al., 2016, Stranc et al., 1997). In addition to their use in genetic
107	diagnosis, first trimester chorionic villus tissue has become a robust platform for investigation of
108	placental pathobiology (Flowers et al., 2021, Gonzalez et al., 2021, Pisarska et al., 2016).
109	
110	In this study, we derived patient-specific human TS cell lines from clinically available
111	chorionic villus tissue. Derivation of TS cell lines from chorionic villus tissue expands the genetic

112 diversity of available human TS cells and importantly is linked to clinical data describing

113 pregnancy outcomes.

#### 114 **Results**

#### 115 Derivation of TS cells from chorionic villus biopsies

116 Chorionic villus biopsies were acquired with patient consent as part of standard medical 117 care. Surplus tissue fragments not used for clinical genetic testing were placed in culture 118 medium used for the expansion of human TS cells (Takahashi et al., 2019); Fig. 1A). Tissue 119 pieces attached to type IV collagen-coated tissue culture treated plates (Fig. 1B). Cell 120 outgrowths were evident at sites of attachment and expanded over the first several weeks of 121 culture (Fig. 1C). Cells and tissue fragments were passaged prior to reaching confluency and 122 replated in 24 well plates. Cell colonies emerged after first passage and steadily expanded with 123 culture medium changes every two days. Colony morphology and growth rates were 124 heterogeneous for the first few passages but became more homogenous after 5-6 passages. The morphology of chorionic villus-derived TS (**TS**<sup>CV</sup>) cells was consistent with the morphology 125 of cytotrophoblast-derived TS cells (TS<sup>CT</sup>; Fig. 1B, Fig. 2A). TS<sup>CV</sup> cell line expansion was 126 127 carried out slowly to reduce clonal pressure on derived cells. Cell lines were slowly transitioned 128 into 6 well and 10 cm plate formats after passages 3-4 and 7-8, respectively (Fig. 1C), Newly 129 established cell lines were cryopreserved beginning at passage 6. Importantly, TS<sup>CV</sup> cells 130 tolerated cryopreservation. Revived cells survived, attached, and proliferated for further 131 expansion. Overall, TS<sup>CV</sup> cell line derivation required approximately three months from sample 132 acquisition to functional assessments of derived lines.

133

The success rate of TS<sup>CV</sup> line derivation was 42%, with ten TS<sup>CV</sup> lines (6 XY; 4 XX) successfully derived from 24 unique patient tissue specimens (15 XY; 9 XX; **Table S1**). Success in cell line derivation may be impacted by the negative consequences of overnight shipping or the cellular contents of the tissue fragments but did not appear to be associated with the clinical karyotype of the CVS specimens. Maternal age range was 30-46 with a mean age of 37.3 years. Maternal and paternal ancestries were self-reported and varied (**Table S1**). Chorionic

140 villus specimen collection ranged from 10-14 weeks gestation with an average gestation age of 141 12 weeks, 3 days (87 days). The earliest sample was collected at 10 weeks, 6 days gestation 142 and the latest sample was collected at 14 weeks of gestation. The amount of starting tissue 143 available for cell line derivation ranged from 5-20 mg with a mean of 8.5 mg of tissue. Clinical 144 genetics performed on tissue specimens at the time of CVS indicated that 19 samples had 145 normal karyotypes (13 samples 46, XY and 6 samples 46, XX). Clinical karyotyping of the 146 remaining five samples reported genomic abnormalities including two samples with trisomy 18 147 (47, XX, +18 and 47, XY, +18), one sample with trisomy 21 (47, XX, +21), and two samples with chromosomal translocations (**Table S1**). The ten derived TS<sup>CV</sup> cell lines were from eight 148 samples with clinically normal karyotypes (TS<sup>CVK01</sup>, TS<sup>CVK05</sup>, TS<sup>CVK09</sup>, TS<sup>CVK19</sup>, TS<sup>CVK21</sup>, TS<sup>CVK22</sup>, 149 150 TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>), one with trisomv 21 (TS<sup>CVK08</sup>) and one with a translocation (TS<sup>CVK07</sup>). Additional phenotypic characterization was performed on a subset of TS<sup>CV</sup> cell lines with 46, XX 151 152 or 46, XY karvotypes.

153

## 154 Characterization of TS<sup>cv</sup> cells in the stem state

155 Karyotyping was repeated on TS<sup>CV</sup> cells following line derivation and expansion. Cell line 156 karyotypes were largely consistent with the clinical karyotyping (Table S1). Karyotypes of TS<sup>CVK01</sup> and TS<sup>CVK24</sup> lines were normal and consistent with the clinical results. TS<sup>CVK09</sup> and 157 158 TS<sup>CVK23</sup> cell lines exhibited mosaicism and were not consistent with the clinical results. A subset 159 of the cells karyotyped for TS<sup>CVK09</sup> were 46, XY. The remaining cells analyzed displayed other 160 genetic anomalies; however, each individual anomaly was restricted to 1-2 total cells (Table 161 **S1**). A subset of TS<sup>CVK23</sup> cells were identified as mosaic for trisomy 20 (47, XX, +20) following 162 cell line derivation.

163  $TS^{CT27}$  (XX) and  $TS^{CT29}$  (XY) served as reference standard human TS cell lines (Okae et 164 al., 2018) used for comparative characterization of the  $TS^{CV}$  cell lines.  $TS^{CV}$  cells were

165 maintained in a stem/proliferative state and propagated beyond the Havflick limit of 50 cell 166 divisions for non-stem cells, which is consistent with TS<sup>CT</sup> cell proliferation (Okae et al., 2018). Established TS<sup>CV</sup> cell lines were assessed for presence of mycoplasma by quantitative 167 polymerase chain reaction (**qPCR**) and no evidence of contamination was detected. TS<sup>CV</sup> cells 168 169 in the stem state grew in discrete colonies and displayed a cobblestone morphology, consistent with the morphology of cytotrophoblast-derived cell lines, TS<sup>CT27</sup> and TS<sup>CT29</sup> ((Okae et al., 2018); 170 Fig. 2A). TS<sup>CV</sup> cells displayed additional characteristics consistent with their trophoblast cell 171 172 identity (Lee et al., 2016), including expression of microRNAs from the Chromosome 19 173 microRNA cluster (Fig. 2B; C19MC; hsa-miR-517a-3p, has-miR-517-5p, and hsa-miR-526b-3p) 174 and hypomethylation of the E74 Like ETS Transcription Factor 5 (ELF5) promoter relative to induced pluripotent stem (**iPS**) cells (**Fig. 2C**). Overall, TS<sup>CV</sup> and TS<sup>CT</sup> cells cultured in the stem 175 176 state displayed similar proliferative, morphologic, microRNA expression, and methylation 177 properties. 178 Analysis of the differentiation capacity of TS<sup>cv</sup> cells 179 Comparisons of TS<sup>CV</sup> and TS<sup>CT</sup> cell capacities for differentiation into STB and EVT cell 180 181 lineages, were performed following cell line derivation (Fig. 1C). Assessments of cell 182 differentiation were routinely performed following 10 passages. Differentiation was assessed at 183 morphological and functional levels. 184 **STB differentiation**. The ability of TS<sup>CV</sup> cells to differentiate into STB was assessed 185 186 using the previously described three-dimensional STB (ST3D) protocol (Okae et al., 2018). STB 187 differentiation elicited significant morphological changes, including the formation of suspended spheroid cell clusters (Fig. 3A). Complementary to the morphological changes observed. TS<sup>CV</sup>-188 189 derived STB displayed downregulation of stem state transcripts TEAD4, LRP2, and LIN28A

190 (Fig. 3B) and upregulation of STB lineage-specific transcripts, including cytochrome P450

191 Family 11 Subfamily 1 (CYP11A1), chorionic gonadotropin beta 7 (CGB7), and syndecan 1 (SDC1; Fig. 3C). STB differentiated from TS<sup>CV</sup> cells secreted chorionic gonadotropin (CG) at 192 levels comparable to STB differentiated from TS<sup>CT</sup> cells as measured by ELISA (**Fig. 3D**). 193 194 Overall, TS<sup>CV</sup>-derived STB had similar cell morphology, expression patterns of signature STB transcripts, and CG production that is observed in TS<sup>CT</sup>-derived STB. 195 196 EVT cell differentiation. Canonical features of EVT cell differentiation observed in TS<sup>CT</sup> 197 cells were evident in TS<sup>CV</sup> cell lines with normal karyotypes (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and 198 TS<sup>CVK24</sup>), including elongated cell morphology (Fig. 4A; Videos 1-3) and expression of major 199 200 histocompatibility complex, class I, G (HLA-G) protein (Fig. 4B). EVT cells displayed 201 downregulation of stem state transcripts TEAD4, LRP2, and LIN28A (Fig. 4C). Characteristic 202 EVT transcripts were upregulated, including HLA-G, matrix metallopeptidase 2 (MMP2), and C-C motif chemokine receptor 1 (*CCR1*; Fig. 4D). Overall, these TS<sup>CV</sup> stem cell derived EVT cells 203 were comparable to EVT cells derived from TS<sup>CT</sup> cells. 204 205 Transcriptomic analysis of the developmental potential of TS<sup>cv</sup> cells 206 To obtain a broad comparative assessment of TS<sup>CV</sup> and TS<sup>CT</sup> in stem, STB, and EVT 207 208 differentiated cell states, transcriptomes were captured using RNA-sequencing (RNA-seq). STB 209 differentiation from the stem state resulted in broad changes in gene expression in TS<sup>CT</sup> cells (TS<sup>CT27</sup>, TS<sup>CT29</sup>; Fig. 5A; Table S2) and TS<sup>CV</sup> cells (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>; Fig. 210 211 5B; Table S3), including downregulation of stem markers EPCAM, LIN28A, LRP2, PEG10, and 212 TEAD4 and upregulation of STB markers CGB2, CGB7, CYP11A1, CYP19A1, and SDC1. STB 213 differentiation-induced changes in gene expression were consistent between TS<sup>CT</sup> (TS<sup>CT27</sup> and TS<sup>CT29</sup>) and TS<sup>CV</sup> (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>) cells (R=0.87, p<2.23-16; **Fig. 5C**). 214 215 EVT cells successfully differentiated from the stem state exhibited broad gene expression changes in TS<sup>CT</sup> (TS<sup>CT27</sup>, TS<sup>CT29</sup>; Fig. 5D; Table S4) and TS<sup>CV</sup> cell lines with normal 216

karyotypes (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>; **Fig. 5E; Table S5**). These changes included 217 218 the downregulation of stem markers EPCAM, LIN28A, LRP2, PEG10, and TEAD4 and upregulation of EVT cell markers CCR1, HLA-G, ITGA1, MMP2, and NOTUM. Gene expression 219 changes induced by EVT cell differentiation were consistent between TS<sup>CT</sup> (TS<sup>CT27</sup> and TS<sup>CT29</sup>) 220 and TS<sup>CV</sup> (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>) cells (R=0.85, p<2.23-16; **Fig. 5F**). 221 Principal component analysis of TS<sup>CT</sup> and TS<sup>CV</sup> cell lines identified three primary cell-222 state specific clusters (Fig. 5G). TS<sup>CV</sup> cells displayed consistent clustering in the stem state and 223 224 following STB and EVT cell lineage differentiation (Fig. 5G). Results from correlation analyses 225 performed to compare cell expression profiles are indicative of comparable transcriptomic changes across TS<sup>CV</sup> and TS<sup>CT</sup> cell lines (**Fig. 5H**). Overall, these results indicate that TS<sup>CV</sup> cells 226 227 are capable of self-renewal and effective differentiation into both STB and EVT cell lineages and 228 can be considered bonafide TS cells.

229

## 230 Discussion

231 Our understanding of placenta development and function has benefitted from the 232 availability of in vitro model systems. In the human, these model systems have included primary 233 cell and explant cultures, choriocarcinoma-derived cell lines, and immortalized cell lines (Ringler 234 and Strauss, 1990, Shibata et al., 2020). Each in vitro approach has had merits but also 235 limitations (Lee et al., 2016, Soares et al., 2018). Over two decades ago, Rossant and 236 colleagues reported a procedure for culturing TS cells from the mouse (Tanaka et al., 1998). 237 These cells could be maintained in a proliferative stem state or induced to differentiate. 238 Furthermore TS cells could be reintroduced into blastocysts and shown to possess the capacity 239 to contribute to mouse placentas (Tanaka et al., 1998). Mouse TS cells became an effective 240 model system to elucidate gene regulatory networks controlling trophoblast cell differentiation 241 and placental development (Hada et al., 2022, Hemberger et al., 2020, Latos and Hemberger, 242 2016, Lee et al., 2019). Efforts ensued to establish TS cells in other species with some success

243 (Asanoma et al., 2011, Grigor'eva et al., 2009) but human TS cells represented an enigma 244 (Kunath et al., 2014, Shibata et al., 2020). Culture protocols for sustaining mouse TS cells were 245 ineffective in the human (Kunath et al., 2014). The discovery of culture conditions for 246 propagating and differentiating human TS cells represented a major advancement (Okae et al., 247 2018). Utilizing these human TS cell culture tools, we have demonstrated the feasibility of 248 capturing and expanding authentic TS cells from human chorionic villus specimens. Unique to 249 these newly derived stem cells is the ability to obtain clinical outcomes that can be used to study 250 placental development leading to healthy outcomes and disease states.

251

252 The initial human TS cell lines were derived from either blastocysts or first trimester 253 pregnancy terminations (Okae et al., 2018). These human TS cell lines represent the 254 benchmark for all TS cell lines subsequently derived. Chorionic villus biopsies are an alternative 255 tissue source for deriving TS cells. They are retrieved during the first trimester of pregnancy as 256 part of standard medical care (Adusumalli et al., 2007, Dong et al., 2003, McIntosh et al., 1993, 257 Pisarska et al., 2016, Stranc et al., 1997, Wang et al., 1994, Williams et al., 1992, Williams et 258 al., 1987). Thus, chorionic villus-derived TS cell lines can be connected to robust pregnancy 259 outcome information. Human TS cell lines have also been derived from miscarriages (Saha et 260 al., 2020), term human placenta tissue (Wang et al., 2022), and reprogrammed from pluripotent 261 stem cells (Castel et al., 2020, Cinkornpumin et al., 2020, Dong et al., 2020, Guo et al., 2021, lo 262 et al., 2021, Jang et al., 2022, Liu et al., 2020, Soncin et al., 2022, Viukov et al., 2022, Wei et 263 al., 2021, Yanagida et al., 2021). These alternative TS cell models are potentially useful tools for 264 investigating trophoblast cell development but each offer caveats for consideration. TS cells 265 derived from trophoblast tissue obtained from miscarriages may best contribute to 266 understanding trophoblast cell-related mechanisms linked to pregnancy failure and the impact of 267 a failed pregnancy on TS cells. TS cells recovered from term placental tissue reflect the 268 culmination of events transpiring throughout the duration of pregnancy, as epigenomic

269 differences are observed in the placenta during gestation (Flowers et al., 2021, Gonzalez et al., 270 2021). Pluripotency is established through extensive genomic reprogramming (Hanna et al., 271 2010, Papp and Plath, 2013), which minimizes the impact of the epigenetic landscape 272 established during pregnancy on the TS cell phenotype. It is reasonable to assume that genetic 273 background and source of trophoblast tissue for TS derivation will influence TS cell behavior. 274 Culturing TS cells under optimized conditions may normalize some features attributed to an 275 adverse pregnancy and maternal environment, whereas in other cases the aberrant behavior 276 may persist. Advantages of using chorionic villus-derived TS cells for investigating trophoblast 277 cell-gene regulatory networks contributing to placental development are evident.

278

279 TS cell lines were successfully derived from chorionic villus biopsies possessing both 280 normal and abnormal karyotypes. TS cells with a triploid karyotype have also been established 281 from human blastocysts (Kong et al., 2022). Most recently, trophoblast organoids with abnormal 282 karyotypes have been derived from chorionic villus biopsies (Schaffers et al., 2022). Chorionic 283 villus-derived TS cell lines could be interrogated in the stem state and following differentiation 284 into either STB or EVT cell lineages. The phenotypic and functional parameters evaluated 285 revealed similarities between cytotrophoblast and chorionic villus-derived TS cells when 286 cultured for stem state maintenance or following STB and EVT cell differentiation. Some 287 differences in the capacity for EVT cell differentiation among chorionic villus-derived TS cells 288 were noted. Variability in the capacity for human TS cell line differentiation into EVT cells has 289 been previously reported (Cinkornpumin et al., 2020, Haider et al., 2022, Okae et al., 2018, 290 Shannon et al., 2022). Numerous factors such as unreported clinical characteristics, undetected 291 genomic differences, or inherent sample variability could be contributing to the differences 292 observed. Thus, chorionic villus-derived TS cells represent a unique in vitro model to investigate 293 functional variability in TS cells isolated from a temporally relevant tissue source. The true 294 impact of the chromosomal abnormalities on TS cells and their differentiation into STB or EVT

cells will require successful cultivation and characterization of multiple cell lines possessing thesame abnormal karyotype.

297

298 Mosaicism is a characteristic feature of the human placenta (Coorens et al., 2021, 299 Robinson and Del Gobbo, 2021, Yuen and Robinson, 2011). Trophoblast cells possess a 300 tolerance for karyotypic abnormalities not evident in the embryo or fetus (Coorens et al., 2021, 301 Shahbazi et al., 2020, Yuen and Robinson, 2011). Each cotyledon of the placenta exhibits 302 elements of trophoblast cell clonality (Coorens et al., 2021). Placental mosaicism is manifested 303 in genetic and functional differences among cotyledons within a human placenta (Coorens et al., 304 2021, Huang et al., 2009, Rubin et al., 1993, Wang et al., 1993). Among the TS cell lines 305 derived from chorionic villus biopsies, some exhibited a karyotype consistent with the karyotype 306 of chorionic villus tissue used for the clinical genetic analysis, whereas others differed. Chorionic 307 villus biopsies contain a mixture of trophoblast and extraembryonic mesoderm (Aplin and Jones, 308 2021). Thus, differences in TS cell versus chorionic villus tissue could be attributed to confined 309 placental mosaicism or alternatively, linked to an unappreciated consequence of culture 310 conditions required to establish the TS cell lines. 311 312 In summary, the generation of chorionic villus biopsy-derived human TS cell lines 313 expand the genetic diversity of existing TS cell lines available for basic research and importantly 314 provides an opportunity to associate pregnancy outcomes with trophoblast cell biology. The 315 research also offers insights into the significance of genetic anomalies and mosaicism in 316 trophoblast cell development and introduces a novel precision medicine approach to the study 317 of placentation.

318

#### 319 Materials and Methods

320 Chorionic villus tissue collections, karyotypic analysis, and clinical phenotyping

321 Chorionic villus tissue was obtained by highly experienced perinatologists as part of 322 standard medical care between 10-14 weeks of gestation for clinical genetic diagnosis at 323 Cedars-Sinai Medical Center (Huang et al., 2009, Pisarska et al., 2016). Clinical cytogenetic 324 analysis was performed on tissue specimens by direct and long-term culture and reviewed by a 325 team of cytogeneticists (Huang et al., 2009). Residual trophoblast tissue fragments not required 326 for clinical cytogenetic analysis were recovered, suspended in Complete TS Cell Medium 327 [DMEM/F12 (11320033, Thermo Fisher, Waltham, MA), 100 µM 2-mercaptoethanol, 0.2% 328 (vol/vol) fetal bovine serum (FBS), 50 µM penicillin, 50 U/mL streptomycin, 0.3% bovine serum 329 albumin (BSA, BP9704100, Thermo Fisher), 1% Insulin-Transferrin-Selenium-Ethanolamine 330 (ITS-X) solution (vol/vol, 51500056, Thermo Fisher)], 8.5 µM L-ascorbic acid (A8960, Sigma-331 Aldrich, St. Louis, MO), 50 ng/mL epidermal growth factor (EGF, E9644, Sigma-Aldrich), 2 µM 332 CHIR99021 (04-0004, Reprocell, Beltsville, MD), 0.5 µM A83-01 (04-0014, Reprocell), 1 µM 333 SB431542 (04-0010, Reprocell), 800 µM valproic acid (P4543, Sigma-Aldrich), and 5 µM 334 Y27632 (04-0012-02, Reprocell)] (Okae et al., 2018), shipped overnight to the University of 335 Kansas Medical Center, and used for TS cell derivation. Demographic data was collected from 336 patients and included, parental ages, races and ethnicities, and ancestry (Table S1).

337

## 338 Derivation of TS cells from chorionic villus tissue specimens

339 Chorionic villus biopsy tissue fragments were dissected and transferred in complete 340 human TS cell medium. Briefly, individual villus fragments were minced and transferred to a 341 1.7mL tube, washed with PBS, and centrifuged at 500 x g for 3 min. Tissue pellets were resuspended in HBSS (with Ca<sup>2+</sup> and Mg<sup>2+</sup>) supplemented with 1.25U/ml dispase II, 0.4mg/ml 342 343 collagenase IV and 80 U/ml DNase I. Samples were then agitated for 15 min at 37°C. After 344 incubation, tissue suspensions were centrifuged at 500 x g for 3 min. and washed with basal TS 345 cell medium. Finally, cells and tissue suspensions were centrifuged at 500 x q for 3 min, 346 resuspended in complete human TS cell medium and plated in 5 mg/mL Corning® mouse type

347 IV collagen (35623, Discovery Labware Inc., Billerica, MA) coated dishes containing complete human TS cell medium. Cells and remaining tissue fragments attached within 2-5 days. Medium 348 349 was replaced with fresh TS cell culture medium after initial attachment and every two days 350 thereafter. Time to first passage was unique to each sample and determined by the extent of the 351 outgrowth, but commonly occurred around 21 days post plating. Cells and attached tissue 352 fragments were washed with PBS and detached with TrypLE Express (12604021, Thermo 353 Fisher). Cell and tissue fragments were replated in human TS cell culture conditions in a 24 well 354 plate format. Colonies emerged after the first passage. Cells were maintained in 24 well plate 355 format for 3-5 passages and then expanded into 6 well plate format. 356

## 357 **TS cell culture**

358 Following TS cell derivation, TS cells were cultured in dishes pre-coated with iMatrix511 359 (1:2000 dilution; NP892-01, Reprocell). TS cells were maintained in Modified Complete TS Cell 360 Medium [DMEM/F12 (11320033, Thermo Fisher), 50 U/mL penicillin, 50 µg/mL streptomycin, 361 0.15% BSA (BP9704100, Thermo Fisher), 1% ITS-X solution (vol/vol; 51500056, Thermo 362 Fisher)], 200 µM L-ascorbic acid (A8960, Sigma-Aldrich), 1% KnockOut Serum Replacement 363 (KSR, 10828028, Thermo Fisher), 25 ng/mL EGF (E9644, Sigma-Aldrich), 2 µM CHIR99021 364 (04-0004, Reprocell), 5 µM A83-01 (04-0014, Reprocell), 800 µM valproic acid (P4543, Sigma-365 Aldrich), and 2.5 µM Y27632 (04-0012-02, Reprocell)] (Takahashi et al., 2019) medium was replaced every two days of culture. TS<sup>CT27</sup> (XX) and TS<sup>CT29</sup> (XY) (Okae et al., 2018) were used 366 367 as reference lines.

368

### 369 STB differentiation

To induce STB cell differentiation, TS cells were plated into 6 cm petri dishes at a
density of 300,000 cells per dish and cultured in ST3D Medium [DMEM/F12 (11320033, Thermo
Fisher), 50 U/mL penicillin, 50 µg/mL streptomycin, 0.15% BSA (BP9704100, Thermo Fisher),

373 1% ITS-X solution (vol/vol; 51500056, Thermo-Fisher)], 200 µM L-ascorbic acid (A8960, Sigma-374 Aldrich), 5% KSR (10828028, Thermo Fisher), 2.5 µM Y27632 (04-0012, Reprocell), 2 µM 375 forskolin (F6886, Sigma-Aldrich), and 50 ng/mL of EGF (E9644, Sigma-Aldrich)](Okae et al., 376 2018). On day 3 of cell differentiation, 3 mL of fresh ST3D medium was added to the culture 377 dishes. Cells were analyzed on day 6 of STB cell differentiation. 378 379 **EVT cell differentiation** 380 EVT cell differentiation was induced by plating human TS cells onto 6-well plates pre-381 coated with 1 µg/mL of mouse type IV collagen at a density of 80,000 cells per well. Cells were 382 cultured in EVT Differentiation Medium [DMEM/F12 (11320033, Thermo Fisher), 100 µm 2-383 mercaptoethanol, 50 U/mL penicillin, 50 µg/mL streptomycin, 0.3% bovine serum albumin 384 (BP9704100, Thermo Fisher), 1% Insulin-Transferrin-Selenium-Ethanolamine solution (vol/vol; 385 51500056, Thermo Fisher)], 100 ng/mL of neuregulin 1 (**NRG1**, 5218SC, Cell Signaling, 386 Danvers, MA), 7.5 µM A83-01 (04-0014, Reprocell), 2.5 µM Y27632 (04-0012, Reprocell), 4% KSR (10828028, Thermo Fisher), and 2% Matrigel<sup>®</sup> (CB-40234, Thermo Fisher). On day 3 of 387 388 EVT cell differentiation, the medium was replaced with EVT Differentiation Medium excluding 389 NRG1 and with a reduced Matrigel<sup>®</sup> concentration of 0.5%. On day 6 of EVT cell differentiation, 390 the medium was replaced with EVT Differentiation Medium with a Matrigel<sup>®</sup> concentration of 391 0.5% and excluding NRG1 and KSR. Cells were analyzed on day 8 of EVT cell differentiation. 392 393 Cell line karyotyping Chromosome analysis of TS<sup>CV</sup> cells was performed using standard cytogenetic methods 394 395 (Huang et al., 2009, Pisarska et al., 2016). GTG banded chromosomes were analyzed at 450-

396 550 band levels. Cytogenetic and fluorescence in situ hybridization results were described

397 according to the current International Standing Committee on Human Cytogenetic

398 Nomenclature (ISCN, 2009).

### 399

# 400 Immunocytochemical analysis

401	Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room
402	temperature. Fixed cells were incubated with primary antibody against HLA-G (ab52455,
403	Abcam), followed by Alexa488-conjugated goat-anti-mouse immunoglobulin G (IgG; A32723,
404	Thermo Fisher Scientific) secondary antibody and 4',6-diamidino-2-phenylindole (DAPI;
405	Molecular Probes, Eugene, OR). Fluorescence images were captured on a Nikon 80i upright
406	microscope (Nikon) with a Photometrics CoolSNAP-ES monochrome camera (Roper
407	Technologies, Inc., Sarasota, FL).
408	
409	iPS cell culture
410	Human iPS cells were propagated in tissue culture plates pre-coated with ${\sf Matrigel}^{\scriptscriptstyle \otimes}$
411	(1:100 dilution; 356231, Corning Life Sciences, Tewksbury, MA). iPS cells were maintained in
412	complete iPS Cell Medium [mTeSR1 Basal Medium + mTeSR1 5X Supplement (85850,
413	STEMCELL Technologies, Inc., Vancouver, CA) and 10 $\mu$ M Y27632 (04-0012-02, Reprocell)]
414	and incubated at $37^{\circ}$ C and $5\%$ CO <sub>2</sub> . After the first day of culture, cells were cultured in complete
415	iPS cell medium without Y27632. Medium was replaced every other day of culture. Cells were
416	passaged or harvested at 80% confluency.
417	
418	miRNA isolation, cDNA preparation, and quantitative real-time PCR
419	Total RNA was isolated using mirVana kit (AM1560, Thermo Fisher), and RNA
420	concentration was measured with the Qubit™ RNA BR Assay Kit (Thermo Fisher). cDNA
421	synthesis was performed with TaqMan $^{I\!R}$ Advanced miRNA cDNA Synthesis kit (A28007,
422	Thermo Fisher). RT-qPCR was performed using TaqMan™Fast Advanced Master Mix
423	(4444556, Thermo Fisher) and targeted miRNAs MIR517a-3p, MIR517-5p, MIR-526b-3p, and
424	housekeeping miRNA MIR103a-3p (479485_mir, 478996_mir, and 478253_mir; TaqMan™

425	Advanced miRNA Assays, Thermo Fisher; Table S6). Relative expression of each transcript
426	was calculated using $\Delta\Delta$ CT method and normalized to hsa-miR-103a-3p.

427

#### 428 **Methylation analysis**

429 Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (69504, Qiagen,

430 Germantown, MD), and 500 ng of DNA was bisulfite converted using the EZ DNA Methylation-

431 Gold Kit (D5005, Zymo Research, Irvine, CA) according to instructions. Following bisulfite

432 conversion, the ELF5 promoter region was amplified using a nested PCR approach with

433 previously reported primers (Primer Set A: forward: 5'-GGAAATGATGGATATTGAATTTGA-3';

434 reverse: 5'-CAATAAAAATAAAAACACCTATAACC-3' Primer Set B: forward: 5'-

435 GAGGTTTTAATATTGGGTTTATAATG-3'; reverse: 5'-ATAAATAACACCTACAAACAAATCC-3';

436 **Table S7**; (Lee et al., 2016, Soncin et al., 2022). PCR was performed with a hot start DNA

437 polymerase, ZymoTaq (E2001, Zymo Research). After the second PCR, Taq polymerase-

438 amplified PCR products were gel-purified with QIAquick Gel Extraction Kit (28706X4, Qiagen),

439 using manufacturer protocols. The purified DNA was inserted directly into a plasmid vector

440 using TOPO® TA Cloning® Kits for Sequencing (450030, Thermo Fisher) according to

441 manufacturer instructions. One microliter of purified PCR product was cloned into the plasmid

442 vector (pCR™4-TOPO®) for 5 min at room temperature. Competent *E. coli* cells were

transformed with the pCR4-TOPO construct, cultured, and minipreps were prepared using the

444 QIAprep Spin Miniprep Kit (27106X4, Qiagen). Purified DNA was sequenced (GENEWIZ, South

445 Plainfield, NJ).

446

#### 447 CG enzyme-linked immunosorbent assay (ELISA)

448 Conditioned medium was collected following six days of STB culture for each cell line.

449 CG levels were measured using an ELISA kit (HC251F, Calbiotech), following the

450 manufacturer's protocol. The measurements were normalized to total cell protein content.

451

#### 452 **RNA isolation and RT-qPCR**

453 Total RNA was isolated using TRIzol<sup>®</sup>/chloroform precipitation (15596018, Thermo 454 Fisher) as previously reported (Varberg et al., 2021). cDNA was synthesized from 1 µg of total 455 RNA using the High-Capacity cDNA Reverse Transcription Kit (4368813, Thermo Fisher) and 456 diluted 10 times with ultra-pure distilled water. gPCR was performed using PowerSYBR<sup>®</sup> Green 457 PCR Master Mix (4367659, Thermo Fisher) and primers (250 nM each). RT-gPCR primer 458 sequences are presented in **Table S8**. Amplification and fluorescence detection were measured 459 with a QuantStudio 5 Flex Real-Time PCR System (Thermo Fisher). An initial step (95°C, 10 460 min) preceded 40 cycles of a two-step PCR (92°C, 15 s; 60°C, 1 min) and was followed by a 461 dissociation step (95°C, 15 s; 60°C, 15 s; 95°C 15 s). The comparative cycle threshold method was used for relative quantification of the amount of mRNA for each sample normalized to the 462 463 housekeeping genes B2M or POLR2A.

464

#### 465 **RNA library preparation and RNA-Seq**

466 Stranded mRNA-sequencing was performed on the Illumina NovaSeg 6000 Sequencing 467 System in the Genomics Core at the University of Kansas Medical Center. Quality control was 468 completed with the RNA Screen Tape Assay kit (5067-5576, Agilent Technologies, Santa Clara, 469 CA) on the Agilent TapeStation 4200. Total RNA (1 µg) was processed in the following steps: i) 470 oligo dT bead capture of mRNA, ii) fragmentation, iii) reverse transcription, iv) cDNA end repair, 471 v) Unique Dual Index (UDI) adaptor ligation, vi) strand selection, and vii) library amplification 472 using the Universal Plus mRNA-Seg with NuQuant library preparation kit (0520-A01, Tecan 473 Genomics, Männedorf, Switzerland). Library validation was performed with the D1000 Screen 474 Tape Assay kit (5067-5582, Agilent Technologies) on the Agilent Tape Station 4200. Library 475 concentrations were determined with the NuQuant module using a Qubit 4 Fluorometer (Thermo

476 Fisher). Libraries were pooled based on equal molar amounts and the multiplexed pool was 477 quantified, in triplicate, using the Roche Lightcycler96 with FastStart Essential DNA Green 478 Master (06402712001, Roche, Indianapolis, IN) and KAPA Library Quant (Illumina, Inc., San 479 Diego, CA) DNA Standards 1-6 (KK4903, KAPA Biosystems, Wilmington, MA). Using the gPCR 480 results, the RNA-Seq library pool was adjusted to 2.125 nM for multiplexed sequencing. Pooled 481 libraries were denatured with 0.2 N NaOH (0.04N final concentration), neutralized with 400 mM 482 Tris-HCl, pH 8.0, and diluted to 425 pM. Onboard clonal clustering of the patterned flow cell was 483 performed using the NovaSeg 6000 S1 Reagent Kit (200 cycle, 20012864, Illumina). A 2x101 484 cycle sequencing profile with dual index reads was completed using the following sequence 485 profile: Read 1 – 101 cycles x Index Read 1 – 8 cycles x Index Read 2 – 8 cycles x Read 2 – 486 101 cycles. Sequence data were converted from .bcl to FASTQ file format using bcl2fastg 487 software and de-multiplexed. Raw FASTQ files were trimmed using default parameters (-r 0.1 -d 488 0.03) in Skewer (Version 0.2.2) and reads shorter than 18 bp were discarded. Transcripts were 489 quantified using Kallisto (Version 0.46.2). Differentially expressed genes (FDR of 0.05) were 490 discovered using the Bioconductor package DESeg2 in R (Version 1.32.0).

491

#### 492 Live cell imaging

493 Cells were placed into an EVOS Onstage Incubator attached to an EVOS FL Automated 494 Imaging System (Thermo Fisher). The live cell chamber was maintained at constant 495 temperature (37°C), humidity, and 5% CO<sub>2</sub>. For stem culture, TS cells were maintained in stem 496 state culture conditions described above and images were acquired 1-2 days after passage and 497 immediately following culture medium change. EVT cell differentiation was induced as described 498 above. On the fourth day of the EVT cell differentiation protocol, cells were placed into the live 499 cell chamber. Phase contrast images were acquired every 10 min continuously from days 2-4 of 500 stem cell growth or day 4-6 of EVT cell differentiation.

501

502	Mycoplasma testing
503	Mycoplasma presence was assessed using the LookOut® Mycoplasma qPCR Detection
504	Kit (MP0040A, Sigma-Aldrich). Kit protocols were followed as described.
505	
506	Data availability
507	All raw and processed sequencing data generated in this study have been submitted to
508	the NCBI Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/).
509	
510	Code availability
511	Only publicly available tools were used for data analysis and are described where
512	relevant in the methods.
513	
514	Materials availability
515	Materials will be made available upon reasonable request to the investigators.
516	
517	Statistical analysis
518	Statistical analysis was completed with the GraphPad Prism 9 software. Welch's t tests,
519	Brown-Forsythe and Welch ANOVA tests were applied when appropriate. The figures depict the
520	data represented as mean $\pm$ standard deviation with a statistical significance level of $p$ <0.05.
521	
522	Study Approval
523	All human tissue specimens used for research purposes were collected following
524	informed written consent, deidentified, and approved by institutional review boards at both
525	Cedars-Sinai Medical Center and at the University of Kansas Medical Center.
526	
527	Acknowledgements

528	We thank Stacy Oxley and Brandi Miller for their administrative assistance and Clark
529	Bloomer and Rosanne Skinner in the KUMC Genome Sequencing Facility for their work in
530	library preparation and DNA sequencing. The research was supported by a National Institutes of
531	Health (NIH) National Research Service Award postdoctoral fellowship (F32HD096809) and
532	pathway to independence award (K99HD107262) to K.M.V., NIH grants (MDP: AI154535; MJS:
533	HD020676, HD099638, HD105734), and the Sosland Foundation.
534	Author contributions
535	K.M.V., A.M., M.D.P, and M.J.S. conceived and designed the research; A.N., J.W., and
536	M.D.P. collected and obtained tissue specimens. J.G., I.S., H.O., and T.A. provided reagents,
537	protocols, or equipment; K.M.V., A.M., B.M., and K.I., performed experiments and/or analyzed
538	data; K.M.V, A.M., J.G, I.S., M.D.P, and M.J.S. interpreted results of experiments; K.M.V., A.M.,
539	J.M.V., and M.J.S. prepared figures and drafted manuscript; K.M.V., A.M., M.D.P, and M.J.S.
540	edited and revised manuscript; All authors approved final version of manuscript.
541	
542	Competing Interest Statement
543	There is no conflict of interest that could be perceived as prejudicing the impartiality of
544	the research reported.
545	
546	Diversity and inclusion statement
547	We are committed to promote diversity and inclusion in our research. Our team
548	comprises individuals from varied backgrounds, and we seek to ensure equitable representation
549	and recognition in our work and collaborations.

### 550 References

- 551
- 552 ADUSUMALLI, J., HAN, C. S., BECKHAM, S., BARTHOLOMEW, M. L. & WILLIAMS, J. 553 2007. Chorionic villus sampling and risk for hypertensive disorders of pregnancy. 554 American Journal of Obstetrics and Gynecology, 196, 591.e1-7; discussion 591.e7. 555 AMOROSO, E. C. 1968. The evolution of viviparity. Proceedings of the Royal Society of 556 Medicine, 61, 1188-1200. 557 APLIN, J. D. & JONES, C. J. P. 2021. Cell dynamics in human villous trophoblast. Human 558 Reproduction Update, 27, 904-922. 559 ASANOMA, K., RUMI, M. A. K., KENT, L. N., CHAKRABORTY, D., RENAUD, S. J., 560 WAKE, N., LEE, D.-S., KUBOTA, K. & SOARES, M. J. 2011. FGF4-dependent stem 561 cells derived from rat blastocysts differentiate along the trophoblast lineage. 562 Developmental Biology, 351, 110-119. 563 BHATTACHARYA, B., HOME, P., GANGULY, A., RAY, S., GHOSH, A., ISLAM, M. R., 564 FRENCH, V., MARSH, C., GUNEWARDENA, S., OKAE, H., ARIMA, T. & PAUL, S. 565 2020. Atypical protein kinase C iota (PKC $\lambda/\iota$ ) ensures mammalian development by establishing the maternal-fetal exchange interface. Proceedings of the National Academy 566 567 of Sciences of the United States of America, 117, 14280-14291. 568 BROSENS, I., PUTTEMANS, P. & BENAGIANO, G. 2019. Placental bed research: I. The 569 placental bed: from spiral arteries remodeling to the great obstetrical syndromes. 570 American Journal of Obstetrics and Gynecology, 221, 437-456. 571 BURTON, G. J., FOWDEN, A. L. & THORNBURG, K. L. 2016. Placental origins of chronic 572 disease. Physiological Reviews, 96, 1509-1565. 573 CASTEL, G., MEISTERMANN, D., BRETIN, B., FIRMIN, J., BLIN, J., LOUBERSAC, S., 574 BRUNEAU, A., CHEVOLLEAU, S., KILENS, S., CHARIAU, C., GAIGNERIE, A., 575 FRANCHETEAU, Q., KAGAWA, H., CHARPENTIER, E., FLIPPE, L., FRANÇOIS-576 CAMPION, V., HAIDER, S., DIETRICH, B., KNÖFLER, M., ARIMA, T., BOURDON, 577 J., RIVRON, N., MASSON, D., FOURNIER, T., OKAE, H., FRÉOUR, T. & DAVID, L. 578 2020. Induction of human trophoblast stem cells from somatic cells and pluripotent stem 579 cells. Cell Reports, 33, 108419. 580 CINKORNPUMIN, J. K., KWON, S. Y., GUO, Y., HOSSAIN, I., SIROIS, J., RUSSETT, C. S., 581 TSENG, H.-W., OKAE, H., ARIMA, T., DUCHAINE, T. F., LIU, W. & PASTOR, W. 582 A. 2020. Naive human embryonic stem cells can give rise to cells with a trophoblast-like 583 transcriptome and methylome. Stem Cell Reports, 15, 198-213. 584 COORENS, T. H. H., OLIVER, T. R. W., SANGHVI, R., SOVIO, U., COOK, E., VENTO-585 TORMO, R., HANIFFA, M., YOUNG, M. D., RAHBARI, R., SEBIRE, N., 586 CAMPBELL, P. J., CHARNOCK-JONES, D. S., SMITH, G. C. S. & BEHJATI, S. 2021. 587 Inherent mosaicism and extensive mutation of human placentas. *Nature*, 592, 80-85. 588 DONG, C., BELTCHEVA, M., GONTARZ, P., ZHANG, B., POPLI, P., FISCHER, L. A., 589 KHAN, S. A., PARK, K.-M., YOON, E.-J., XING, X., KOMMAGANI, R., WANG, T., 590 SOLNICA-KREZEL, L. & THEUNISSEN, T. W. 2020. Derivation of trophoblast stem 591 cells from naïve human pluripotent stem cells. eLife, 9, e52504. 592 DONG, L., FALK, R. E., WILLIAMS, J., KOHAN, M. & SCHRECK, R. R. 2003. Tetrasomy 593 12p--unusual presentation in CVS. Prenatal Diagnosis, 23, 101-103. 594 FLOWERS, A. E., GONZALEZ, T. L., JOSHI, N. V., EISMAN, L. E., CLARK, E. L., 595 BUTTLE, R. A., SAURO, E., DIPENTINO, R., LIN, Y., WU, D., WANG, Y.,

596	SANTISKULVONG, C., TANG, J., LEE, B., SUN, T., CHAN, J. L., WANG, E. T.,
597	JEFFERIES, C., LAWRENSON, K., ZHU, Y., AFSHAR, Y., TSENG, HR.,
598	WILLIAMS, J. & PISARSKA, M. D. 2021. Sex differences in microRNA expression in
599	first and third trimester human placenta <sup>†</sup> . Biology of Reproduction, ioab221.
600	GONZALEZ, T. L., EISMAN, L. E., JOSHI, N. V., FLOWERS, A. E., WU, D., WANG, Y.,
601	SANTISKULVONG, C., TANG, J., BUTTLE, R. A., SAURO, E., CLARK, E. L.,
602	DIPENTINO, R., JEFFERIES, C. A., CHAN, J. L., LIN, Y., ZHU, Y., AFSHAR, Y.,
603	TSENG, HR., TAYLOR, K., WILLIAMS, J. & PISARSKA, M. D. 2021, High-
604	throughput miRNA sequencing of the human placenta: expression throughout gestation.
605	Enigenomics, 13, 995-1012.
606	GRIGOR'EVA, E. V., SHEVCHENKO, A. I., MAZUROK, N. A., ELISAPHENKO, E. A.,
607	ZHELEZOVA, A. L. SHILOV, A. G. DYBAN, P. A. DYBAN, A. P. NONIASHVILI.
608	E. M., SLOBODYANYUK, S. Y., NESTEROVA, T. B., BROCKDORFF, N. &
609	ZAKIAN, S. M. 2009, FGF4 Independent Derivation of Trophoblast Stem Cells from the
610	Common Vole, <i>PLoS ONE</i> 4, e7161
611	GUO, G., STIRPARO, G. G., STRAWBRIDGE, S. E., SPINDLOW, D., YANG, J., CLARKE,
612	J., DATTANI, A., YANAGIDA, A., LI, M. A., MYERS, S., ÖZEL, B. N., NICHOLS, J.
613	& SMITH, A. 2021, Human naive epiblast cells possess unrestricted lineage potential.
614	Cell Stem Cell, 28, 1040-1056.e6.
615	HADA, M., MIURA, H., TANIGAWA, A., MATOBA, S., INOUE, K., OGONUKI, N.,
616	HIROSE, M., WATANABE, N., NAKATO, R., FUJIKI, K., HASEGAWA, A.,
617	SAKASHITA, A., OKAE, H., MIURA, K., SHIKATA, D., ARIMA, T., SHIRAHIGE,
618	K., HIRATANI, I. & OGURA, A. 2022. Highly rigid H3.1/H3.2-H3K9me3 domains set
619	a barrier for cell fate reprogramming in trophoblast stem cells. Genes & Development, 36.
620	84-102.
621	HAIDER, S., LACKNER, A. I., DIETRICH, B., KUNIHS, V., HASLINGER, P.,
622	MEINHARDT, G., MAXIAN, T., SALEH, L., FIALA, C., POLLHEIMER, J., LATOS,
623	P. A. & KNÖFLER, M. 2022. Transforming growth factor-β signaling governs the
624	differentiation program of extravillous trophoblasts in the developing human placenta.
625	Proceedings of the National Academy of Sciences of the United States of America, 119,
626	e2120667119.
627	HANNA, J. H., SAHA, K. & JAENISCH, R. 2010. Pluripotency and cellular reprogramming:
628	facts, hypotheses, unresolved issues. Cell, 143, 508-525.
629	HEMBERGER, M., HANNA, C. W. & DEAN, W. 2020. Mechanisms of early placental
630	development in mouse and humans. <i>Nature Reviews. Genetics</i> , 21, 27-43.
631	HORNBACHNER, R., LACKNER, A., PAPUCHOVA, H., HAIDER, S., KNÖFLER, M.,
632	MECHTLER, K. & LATOS, P. A. 2021. MSX2 safeguards syncytiotrophoblast fate of
633	human trophoblast stem cells. Proceedings of the National Academy of Sciences of the
634	United States of America, 118, e2105130118.
635	HUANG, A., ADUSUMALLI, J., PATEL, S., LIEM, J., WILLIAMS, J. & PISARSKA, M. D.
636	2009. Prevalence of chromosomal mosaicism in pregnancies from couples with
637	infertility. Fertility and Sterility, 91, 2355-2360.
638	IO, S., KABATA, M., IEMURA, Y., SEMI, K., MORONE, N., MINAGAWA, A., WANG, B.,
639	OKAMOTO, I., NAKAMURA, T., KOJIMA, Y., IWATANI, C., TSUCHIYA, H.,
640	KASWANDY, B., KONDOH, E., KANEKO, S., WOLTJEN, K., SAITOU, M.,
641	YAMAMOTO, T., MANDAI, M. & TAKASHIMA, Y. 2021. Capturing human

- trophoblast development with naive pluripotent stem cells in vitro. *Cell Stem Cell*, 28, 1023-1039.e13.
- ISCN 2009. ISCN (2009): An international system for human cytogenetic nomenclature, Basel,
   Karger S.
- ISHIUCHI, T., OHISHI, H., SATO, T., KAMIMURA, S., YORINO, M., ABE, S., SUZUKI, A.,
  WAKAYAMA, T., SUYAMA, M. & SASAKI, H. 2019. Zfp281 shapes the
  transcriptome of trophoblast stem cells and Is essential for placental development. *Cell Reports*, 27, 1742-1754.e6.
- JAJU BHATTAD, G., JEYARAJAH, M. J., MCGILL, M. G., DUMEAUX, V., OKAE, H.,
  ARIMA, T., LAJOIE, P., BÉRUBÉ, N. G. & RENAUD, S. J. 2020. Histone deacetylase
  1 and 2 drive differentiation and fusion of progenitor cells in human placental
  trophoblasts. *Cell Death & Disease*, 11, 311.
- JANG, Y. J., KIM, M., LEE, B.-K. & KIM, J. 2022. Induction of human trophoblast stem-like
   cells from primed pluripotent stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, 119, e2115709119.
- KNÖFLER, M., HAIDER, S., SALEH, L., POLLHEIMER, J., GAMAGE, T. K. J. B. &
  JAMES, J. 2019. Human placenta and trophoblast development: key molecular
  mechanisms and model systems. *Cellular and molecular life sciences: CMLS*, 76, 34793496.
- KONG, X., CHEN, X., OU, S., WANG, W. & LI, R. 2022. Derivation of human triploid
   trophoblast stem cells. *Journal of Assisted Reproduction and Genetics*, 39, 1183-1193.
- KUNATH, T., YAMANAKA, Y., DETMAR, J., MACPHEE, D., CANIGGIA, I., ROSSANT, J.
  & JURISICOVA, A. 2014. Developmental differences in the expression of FGF receptors
  between human and mouse embryos. *Placenta*, 35, 1079-1088.
- LATOS, P. A. & HEMBERGER, M. 2016. From the stem of the placental tree: trophoblast stem
   cells and their progeny. *Development (Cambridge, England)*, 143, 3650-3660.
- LEE, B.-K., JANG, Y. J., KIM, M., LEBLANC, L., RHEE, C., LEE, J., BECK, S., SHEN, W. &
   KIM, J. 2019. Super-enhancer-guided mapping of regulatory networks controlling mouse
   trophoblast stem cells. *Nature Communications*, 10, 4749.
- LEE, C. Q. E., GARDNER, L., TURCO, M., ZHAO, N., MURRAY, M. J., COLEMAN, N.,
  ROSSANT, J., HEMBERGER, M. & MOFFETT, A. 2016. What is trophoblast? A
  combination of criteria define human first-trimester trophoblast. *Stem Cell Reports*, 6,
  257-272.
- LIU, X., OUYANG, J. F., ROSSELLO, F. J., TAN, J. P., DAVIDSON, K. C., VALDES, D. S.,
  SCHRÖDER, J., SUN, Y. B. Y., CHEN, J., KNAUPP, A. S., SUN, G., CHY, H. S.,
  HUANG, Z., PFLUEGER, J., FIRAS, J., TANO, V., BUCKBERRY, S., PAYNTER, J.
- M., LARCOMBE, M. R., POPPE, D., CHOO, X. Y., O'BRIEN, C. M., PASTOR, W. A.,
  CHEN, D., LEICHTER, A. L., NAEEM, H., TRIPATHI, P., DAS, P. P., GRUBMAN,
- 680 A., POWELL, D. R., LASLETT, A. L., DAVID, L., NILSSON, S. K., CLARK, A. T.,
- 681 LISTER, R., NEFZGER, C. M., MARTELOTTO, L. G., RACKHAM, O. J. L. & POLO,
- J. M. 2020. Reprogramming roadmap reveals route to human induced trophoblast stem
  cells. *Nature*, 586, 101-107.
- MCINTOSH, N., RUBIN, C., WANG, B. & WILLIAMS, J. 1993. Transcervical CVS sample
   size: correlation with placental location, cytogenetic findings, and pregnancy outcome.
   *Prenatal Diagnosis*, 13, 1031-1036.

- MUTO, M., CHAKRABORTY, D., VARBERG, K. M., MORENO-IRUSTA, A., IQBAL, K.,
  SCOTT, R. L., MCNALLY, R. P., CHOUDHURY, R. H., APLIN, J. D., OKAE, H.,
  ARIMA, T., MATSUMOTO, S., EMA, M., MAST, A. E., GRUNDBERG, E. &
  SOARES, M. J. 2021. Intersection of regulatory pathways controlling hemostasis and
- hemochorial placentation. *Proceedings of the National Academy of Sciences of the United States of America*, 118, e2111267118.
- 693 OKAE, H., TOH, H., SATO, T., HIURA, H., TAKAHASHI, S., SHIRANE, K., KABAYAMA,
  694 Y., SUYAMA, M., SASAKI, H. & ARIMA, T. 2018. Derivation of human trophoblast
  695 stem cells. *Cell Stem Cell*, 22, 50-63.e6.
- PAPP, B. & PLATH, K. 2013. Epigenetics of reprogramming to induced pluripotency. *Cell*, 152, 1324-1343.
- PEREZ-GARCIA, V., LEA, G., LOPEZ-JIMENEZ, P., OKKENHAUG, H., BURTON, G. J.,
   MOFFETT, A., TURCO, M. Y. & HEMBERGER, M. 2021. BAP1/ASXL complex
   modulation regulates epithelial-mesenchymal transition during trophoblast differentiation
   and invasion. *eLife*, 10, e63254.
- PISARSKA, M. D., AKHLAGHPOUR, M., LEE, B., BARLOW, G. M., XU, N., WANG, E. T.,
  MACKEY, A. J., FARBER, C. R., RICH, S. S., ROTTER, J. I., CHEN, Y.-D. I.,
  GOODARZI, M. O., GULLER, S. & WILLIAMS, J. 2016. Optimization of techniques
  for multiple platform testing in small, precious samples such as human chorionic villus
  sampling. *Prenatal Diagnosis*, 36, 1061-1070.
- sampling. *Prenatal Diagnosis*, 36, 1061-1070.
  RINGLER, G. E. & STRAUSS, J. F. 1990. In vitro systems for the study of human placental
- ros endocrine function. *Endocrine Reviews*, 11, 105-123.
- ROBINSON, W. P. & DEL GOBBO, G. F. 2021. Mistakes Are Common; Should We Worry
  about Them? *Trends in Molecular Medicine*, 27, 721-722.
- ROSSANT, J. & TAM, P. P. L. 2017. New Insights into Early Human Development: Lessons for
   Stem Cell Derivation and Differentiation. *Cell Stem Cell*, 20, 18-28.
- RUANE, P. T., GARNER, T., PARSONS, L., BABBINGTON, P. A., WANGSAPUTRA, I.,
  KIMBER, S. J., STEVENS, A., WESTWOOD, M., BRISON, D. R. & APLIN, J. D.
  2022. Trophectoderm differentiation to invasive syncytiotrophoblast is promoted by
  endometrial epithelial cells during human embryo implantation. *Human Reproduction*(Oxford, England), 37, 777-792.
- RUBIN, C. H., WILLIAMS, J. & WANG, B. B. 1993. Discrepancy in mosaic findings between
  chorionic villi and amniocytes: a diagnostic dilemma involving 45,X, 46,XY, and
  47,XYY cell lines. *American Journal of Medical Genetics*, 46, 457-459.
- SAHA, B., GANGULY, A., HOME, P., BHATTACHARYA, B., RAY, S., GHOSH, A., RUMI,
   M. A. K., MARSH, C., FRENCH, V. A., GUNEWARDENA, S. & PAUL, S. 2020.
   TEAD4 ensures postimplantation development by promoting trophoblast self-renewal:
   An implication in early human pregnancy loss. *Proceedings of the National Academy of Sciences of the United States of America*, 117, 17864-17875.
- SCHAFFERS, O. J. M., DUPONT, C., BINDELS, E. M., VAN OPSTAL, D., DEKKERS, D. H.
  W., DEMMERS, J. A. A., GRIBNAU, J. & RIJN, B. B. V. 2022. Single-Cell Atlas of
  Patient-Derived Trophoblast Organoids in Ongoing Pregnancies. *Organoids*, 1, 106-115.
- 729 SHAHBAZI, M. N., WANG, T., TAO, X., WEATHERBEE, B. A. T., SUN, L., ZHAN, Y.,
- 730 KELLER, L., SMITH, G. D., PELLICER, A., SCOTT, R. T., SELI, E. & ZERNICKA-
- 731 GOETZ, M. 2020. Developmental potential of aneuploid human embryos cultured
- beyond implantation. *Nature Communications*, 11, 3987.

733	SHANNON, M. J., BALTAYEVA, J., CASTELLANA, B., WÄCHTER, J., MCNEILL, G. L.,
734	YOON, J. S., TREISSMAN, J., LE, H. T., LAVOIE, P. M. & BERISTAIN, A. G. 2022.
735	Cell trajectory modeling identifies a primitive trophoblast state defined by BCAM
736	enrichment. Development (Cambridge, England), 149, dev199840.
737	SHERIDAN, M. A., ZHAO, X., FERNANDO, R. C., GARDNER, L., PEREZ-GARCIA, V., LI,
738	Q., MARSH, S. G. E., HAMILTON, R., MOFFETT, A. & TURCO, M. Y. 2021.
739	Characterization of primary models of human trophoblast. Development (Cambridge,
740	England), 148, dev199749.
741	SHIBATA, S., KOBAYASHI, E. H., KOBAYASHI, N., OIKE, A., OKAE, H. & ARIMA, T.
742	2020. Unique features and emerging in vitro models of human placental development.
743	Reproductive Medicine and Biology, 19, 301-313.
744	SOARES, M. J., VARBERG, K. M. & IQBAL, K. 2018. Hemochorial placentation:
745	development, function, and adaptations <sup>†</sup> . <i>Biology of Reproduction</i> , 99, 196-211.
746	SONCIN, F., MOREY, R., BUI, T., REQUENA, D. F., CHEUNG, V. C., KALLOL, S.,
747	KITTLE, R., JACKSON, M. G., FARAH, O., DUMDIE, J., MEADS, M., PIZZO, D.,
748	HORII, M., FISCH, K. M. & PARAST, M. M. 2022. Derivation of functional trophoblast
749	stem cells from primed human pluripotent stem cells. Stem Cell Reports, 17, 1303-1317.
750	STRANC, L. C., EVANS, J. A. & HAMERTON, J. L. 1997. Chorionic villus sampling and
751	amniocentesis for prenatal diagnosis. Lancet (London, England), 349, 711-714.
752	SUN, T., GONZALEZ, T. L., DENG, N., DIPENTINO, R., CLARK, E. L., LEE, B., TANG, J.,
753	WANG, Y., STRIPP, B. R., YAO, C., TSENG, HR., KARUMANCHI, S. A.,
754	KOEPPEL, A. F., TURNER, S. D., FARBER, C. R., RICH, S. S., WANG, E. T.,
755	WILLIAMS, J. & PISARSKA, M. D. 2020. Sexually Dimorphic Crosstalk at the
756	Maternal-Fetal Interface. The Journal of Clinical Endocrinology and Metabolism, 105,
757	dgaa503.
758	TAKAHASHI, S., OKAE, H., KOBAYASHI, N., KITAMURA, A., KUMADA, K.,
759	YAEGASHI, N. & ARIMA, T. 2019. Loss of p57KIP2 expression confers resistance to
760	contact inhibition in human androgenetic trophoblast stem cells. Proceedings of the
761	National Academy of Sciences of the United States of America.
762	TANAKA, S., KUNATH, T., HADJANTONAKIS, A. K., NAGY, A. & ROSSANT, J. 1998.
763	Promotion of trophoblast stem cell proliferation by FGF4. Science (New York, N.Y.), 282,
764	2072-2075.
765	TURCO, M. Y. & MOFFETT, A. 2019. Development of the human placenta. Development, 146,
766	dev163428.
767	VARBERG, K. M., IQBAL, K., MUTO, M., SIMON, M. E., SCOTT, R. L., KOZAI, K.,
768	CHOUDHURY, R. H., APLIN, J. D., BISWELL, R., GIBSON, M., OKAE, H., ARIMA,
769	T., VIVIAN, J. L., GRUNDBERG, E. & SOARES, M. J. 2021. ASCL2 reciprocally
770	controls key trophoblast lineage decisions during hemochorial placenta development.
771	Proceedings of the National Academy of Sciences of the United States of America, 118.
772	VIUKOV, S., SHANI, T., BAYERL, J., AGUILERA-CASTREJON, A., OLDAK, B.,
773	SHEBAN, D., TARAZI, S., STELZER, Y., HANNA, J. H. & NOVERSHTERN, N.
774	2022. Human primed and naïve PSCs are both able to differentiate into trophoblast stem
775	cells. Stem Cell Reports, S2213-6711(22)00457-X.
776	WANG, B. B., RUBIN, C. H. & WILLIAMS, J. 1993. Mosaicism in chorionic villus sampling:
777	an analysis of incidence and chromosomes involved in 2612 consecutive cases. Prenatal
778	Diagnosis, 13, 179-190.

- WANG, B. T., PENG, W., CHENG, K. T., CHIU, S. F., HO, W., KHAN, Y., WITTMAN, M. &
  WILLIAMS, J. 1994. Chorionic villi sampling: laboratory experience with 4,000
  consecutive cases. *American Journal of Medical Genetics*, 53, 307-316.
- WANG, L.-J., CHEN, C.-P., LEE, Y.-S., NG, P.-S., CHANG, G.-D., PAO, Y.-H., LO, H.-F.,
   PENG, C.-H., CHEONG, M.-L. & CHEN, H. 2022. Functional antagonism between
   ΔNp63α and GCM1 regulates human trophoblast stemness and differentiation. *Nature Communications*, 13, 1626.
- WEI, Y., WANG, T., MA, L., ZHANG, Y., ZHAO, Y., LYE, K., XIAO, L., CHEN, C., WANG,
  Z., MA, Y., ZHOU, X., SUN, F., LI, W., DUNK, C., LI, S., NAGY, A., YU, Y., PAN,
  G., LYE, S. J. & SHAN, Y. 2021. Efficient derivation of human trophoblast stem cells
  from primed pluripotent stem cells. *Science Advances*, 7, eabf4416.
- WILLIAMS, J., MEDEARIS, A. L., CHU, W. H., KOVACS, G. D. & KABACK, M. M. 1987.
   Maternal cell contamination in cultured chorionic villi: comparison of chromosome Q polymorphisms derived from villi, fetal skin, and maternal lymphocytes. *Prenatal Diagnosis*, 7, 315-322.
- WILLIAMS, J., WANG, B. B., RUBIN, C. H. & AIKEN-HUNTING, D. 1992. Chorionic villus
   sampling: experience with 3016 cases performed by a single operator. *Obstetrics and Gynecology*, 80, 1023-1029.
- YANAGIDA, A., SPINDLOW, D., NICHOLS, J., DATTANI, A., SMITH, A. & GUO, G. 2021.
   Naive stem cell blastocyst model captures human embryo lineage segregation. *Cell Stem Cell*, 28, 1016-1022.e4.
- YUEN, R. K. C. & ROBINSON, W. P. 2011. Review: A high capacity of the human placenta for
   genetic and epigenetic variation: implications for assessing pregnancy outcome.
   *Placenta*, 32 Suppl 2, S136-141.



804 Fig. 1 Deriving TS cells from chorionic villus tissue specimens. A) Simplified schematic 805 depicting the process of obtaining chorionic villi tissue fragments, derivation of TS cells, and 806 then subsequent differentiation into STB and EVT cell lineages. Created with BioRender.com. 807 B) Chorionic villus tissue fragments attach and form cellular outgrowths within a few days of 808 initial plating. Within one to two weeks the outgrowths expand and proliferate across the well. 809 Two to three weeks after plating, the cells were passaged, and colonies emerged. Colony 810 clusters were initially small but proliferated and grew rapidly. Significant heterogeneity is present initially, but subsequent passaging selects for a TS cell population that displays a similar 811 812 morphology to the original TS cell lines (Okae et al., 2018), which possess the ability to

- 813 differentiate into STB and EVT cell lineages. Scale bar represents 250 µm in first panel. All
- other scale bars represent 500 μm. C) An example timeline for TS cell line derivation and
- 815 characterization.



**Fig. 2 Characterization of TS<sup>cv</sup> cells. A)** Stem state phase contrast images of four chorionic villus-derived TS cell lines ( $TS^{CVK01}$ ,  $TS^{CVK09}$ ,  $TS^{CVK23}$ ,  $TS^{CVK24}$ ) alongside images of the reference cytotrophoblast-derived TS cell lines ( $TS^{CT27}$  and  $TS^{CT29}$ ) at different passage 

- 820 numbers (13-20). Scale bars represent 500 μm. **B)** Bar graphs depicting expression of three
- 821 microRNAs (**miR**) from the C19MC cluster (hsa-miR-517a-3p, has-miR-517-5p, and hsa-miR-
- 526b-3p) in  $TS^{CT}$  and  $TS^{CV}$  cell lines relative to induced pluripotent stem (**iPS**) cells, measured
- by RT-qPCR. Data were normalized to the control miRNA, hsa-miR-103a-3p (n=3 samples per
- 824 group; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001). **C)** Plots representing DNA methylation 825 levels in the ELF5 promoter at 11 sites in  $TS^{CT}$  and  $TS^{CV}$  cell lines compared to iPS cells.
- 826 Methylated sites (black) and unmethylated sites (white) are shown for 10 replicates and the
- 827 average percent methylation is listed.



830 **TS<sup>cv</sup> cell line differentiation into STB. A)** Representative phase contrast images of

- cytotrophoblast-derived TS<sup>CT27</sup> and TS<sup>CT29</sup> cells and four chorionic villus-derived TS cell lines possessing a normal karyotype, TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup> cultured under STB 831
- 832
- 833 differentiation conditions. Scale bars represent 250 µm. B-C) Stem cell-associated transcripts
- 834 (B; TEAD4, LRP2, and LIN28A) and STB cell-associated transcripts (C; CYP11A1, CGB7, and
- 835
- 836
- *SDC1*) were quantified by RT-qPCR in stem (black) and STB differentiated (gray) TS<sup>CT27</sup>, TS<sup>CT29</sup>, TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup> cells (n=3 samples per group; \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001). **D)** Chorionic gonadotropin (**CG**) protein levels (mIU/mg protein) were 837
- guantified by ELISA in cell culture supernatants collected from TS<sup>CT</sup> and TS<sup>CV</sup> cultured cells. 838



**Fig. 4 TS<sup>CV</sup> cell line differentiation into EVT cells. A)** Representative phase contrast images of cytotrophoblast-derived TS<sup>CT27</sup> and TS<sup>CT29</sup> cells and four chorionic villus-derived TS cell lines possessing a normal karyotype, TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup> cells cultured under EVT 

- cell differentiation conditions. Scale bars represent 250  $\mu$ m **B)** Immunofluorescence detection of HLA-G (gray) by immunocytochemistry in TS<sup>CT</sup> and TS<sup>CV</sup> cells cultured in the stem state and on 842
- 843
- 844 day 8 of EVT cell differentiation. DAPI (magenta) stains cell nuclei. Scale bars represent 100
- 845 µm. C-D) Stem cell-associated transcripts (C; TEAD4, LRP2, and LIN28A) and EVT cell-
- associated transcripts (D; HLA-G, MMP2, and CCR1) were quantified by RT-qPCR in stem 846
- (black) and EVT differentiated (gray)  $TS^{CT27}$ ,  $TS^{CT29}$ ,  $TS^{CVK01}$ ,  $TS^{CVK09}$ ,  $TS^{CVK23}$ , and  $TS^{CVK24}$  cells (n=3 samples per group; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001). 847
- 848



#### Fig. 5 TS<sup>CV</sup> and TS<sup>CT</sup> cells cluster by cell state and share similar transcriptomes. A-B) 850

851 Volcano plots depicting significantly up- and down-regulated genes based on transcripts measured by RNA-seq in stem versus STB state TS<sup>CT</sup>(**A**) and TS<sup>CV</sup>(**B**) cells. Gene transcript 852

- levels unchanged between stem and STB state cells are depicted in gray (n=3 per group; 853
- absolute Log<sub>2</sub> fold change >1, adjusted p<0.05). **C)** Two-dimensional density plot comparing 854
- gene expression changes between stem and STB cell states in TS<sup>CT</sup> (TS<sup>CT27</sup> and TS<sup>CT29</sup>) cells 855
- versus TS<sup>CV</sup> (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>) cells (Pearson correlation coefficient 856
- (R)=0.87, p<2.2e-16). D-E) Volcano plots depicting significantly up- and down-regulated genes 857
- based on transcripts measured by RNA-seq in stem versus EVT states of TS<sup>CT</sup>(E) and TS<sup>CV</sup>(E) 858
- 859 cells. Gene transcript levels unchanged between stem and EVT state cells are depicted in gray
- 860 (n=3 per group; absolute Log<sub>2</sub> fold change >1, adjusted p<0.05). F) Two-dimensional density plot comparing gene expression changes between stem and EVT cell states in TS<sup>CT</sup> (TS<sup>CT27</sup> and 861
- TS<sup>CT29</sup>) cells versus TS<sup>CV</sup> (TS<sup>CVK01</sup>, TS<sup>CVK09</sup>, TS<sup>CVK23</sup>, and TS<sup>CVK24</sup>) cells (Pearson correlation 862
- coefficient (R)=0.85, p<2.2e-16). G) Principal component analysis based on RNA-seq datasets 863
- generated from TS<sup>CT</sup> and TS<sup>CV</sup> cells cultured in the stem state or following differentiation into 864
- STB and EVT cell lineages. **H)** Heat map showing scaled normalized read counts representing gene expression profiles of stem state, STB, and EVT differentiated cells across TS<sup>CT</sup> and TS<sup>CV</sup> 865
- 866
- 867 cell lines.

#### Video Legends

Video 1. Stem state and EVT-differentiated TS<sup>CT27</sup> cell growth and motility. Phase contrast images were acquired every 10 min for 53 h of TS<sup>CT27</sup> cells cultured under stem state or EVT cell-differentiation conditions (EVT cell differentiation protocol days 4-6).

## 

Video 2. Stem state and EVT cell differentiated  $TS^{CVK01}$  cell growth and motility. Phase contrast images were acquired every 10 min for 53 h of  $TS^{CVK01}$  cells cultured under stem state or EVT cell differentiation conditions (EVT cell differentiation protocol days 4-6).

- Video 3. Stem state and EVT cell differentiated TS<sup>CVK09</sup> cell growth and motility. Phase contrast images were acquired every 10 min for 53 h of TS<sup>CVK09</sup> cells cultured under stem state or EVT cell differentiation conditions (EVT cell differentiation protocol days 4-6).